Prostate cancer is the second most common cancer in men worldwide, after skin cancer. It accounts for 15% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems. While patients diagnosed with early-stage, localized prostate cancer can be cured, patients who are diagnosed with or progress to castration-resistant prostate cancer (CRPC) have no curative options. This report focuses on the current treatment landscape, unmet needs, pipeline assessment and market outlook for prostate cancer. Since 2010, five new drugs have been approved for the treatment of CRPC: Dendreon's Provenge, Sanofi's Jevtana, Johnson & Johnson's Zytiga, Medivation/Astellas' Xtandi, and Bayer's Xofigo. During the forecast period from 2013-2023, We expect that nine new late-stage pipeline agents will launch, eight of which will be for the treatment of CRPC. As a result of this unprecedented level of clinical development, We predict there will be massive changes in the CRPC treatment paradigm. In addition, due to the influx of new therapies, the size of the prostate cancer market across the nine major pharmaceutical markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada) will increase three-fold.
The US is the largest prostate cancer market among the countries covered in this report, and will remain so through the forecast period. The US' dominance of the prostate cancer market is due to the high incidence of the disease, the high drug treatment rate, and higher drug prices compared with all the other markets. Additional factors that will drive growth of the US prostate cancer market include the increasing incidence of prostate cancer as the population ages, increased sales resulting from the launch of eight new premium-priced pipeline products during the forecast period, and the label extension of Xtandi into the nmCRPC and hormone-sensitive prostate cancer patient populations.
Overview of Prostate Cancer including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. •
Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis. •
Sales forecast for the top drugs in the US from 2013-2023. •
Analysis of the impact of key events as well the drivers and restraints affecting the US Prostate Cancer market.